Zydus Lifesciences has informed that it enclosed a copy of press release dated September 15, 2023 titled ‘Zydus receives final approval from the USFDA for Norelgestromin and Ethinyl Estradiol Transdermal System, 150 mcg/35 mcg per day’.
The above information is a part of company’s filings submitted to BSE.